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Introduction
Approximately 30% of women experience heavy menstrual 
bleeding (HMB) or menorrhagia at some point in their repro-
ductive life, which is defined as excessive menstrual blood loss. 
It may occur alone or in combination with other symptoms, 
with a negative impact on a woman’s physical, social, emo-
tional and/or material quality of life [1-4]. Approximately one 
in 20 women in the age group of 30 to 49 years consult their 
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Objective
To compare real-life clinical outcomes with the levonorgestrel-releasing intrauterine system (LNG-IUS) and conventional 
medical therapies (CMTs), including combined oral contraceptives and oral progestins in the treatment of idiopathic 
heavy menstrual bleeding (HMB) in South Korea.
Methods
This prospective, observational cohort study recruited a total of 647 women aged 18 to 45 years, diagnosed with HMB from 
8 countries in Asia, including 209 women from South Korea (LNG-IUS, 169; CMTs, 40), who were followed up to one year. 
The primary outcome was cumulative continuation rate (still treated with LNG-IUS and CMTs) at 12 months. Secondary 
outcomes included bleeding pattern, assessment of the treatment efficacy by treating physician and safety profile.
Results
The continuation rate at 12 months was significantly higher with the LNG-IUS than CMTs (85.1% vs. 48.5%, 
respectively; P<0.0001). The 51.5% of CMTs patients discontinued treatment and 18.8% of LNG-IUS patients 
discontinued treatment. The most common reasons for discontinuation for CMTs were switching to another treatment 
and personal reasons. When compared to CMTs, the LNG-IUS offered better reduction in subjectively assessed 
menstrual blood loss and the number of bleeding days, tolerability and with better efficacy in HMB, as assessed by 
physician’s final evaluation.
Conclusion
This study provides novel information on the real-life treatment patterns of HMB in South Korea. The efficacy of CMTs 
was inferior compared to the LNG-IUS in the clinical outcomes measured in this study. Due to the better compliance 
with LNG-IUS, the cumulative continuation rate is higher than CMTs. We conclude that the LNG-IUS should be used as 
the first-line treatment for HMB in Korean women, in line with international guidelines.
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primary care physician each year for HMB, which is the second 
most common reason for a hospital referral, and accounts for 
12% of all gynecological referrals [5,6]. However, despite this 
significant disease burden, documented evidence on the actual 
clinical practice of HMB care is sparse in the Asia-Pacific region. 
Data from the Caucasian population indicate that levonorg-
estrel-releasing intrauterine system (LNG-IUS; Mirena, Bayer 
HealthCare, Wayne, NY, USA) is a safe and effective treatment 
for HMB [7]. Similarly, small single-site studies conducted in 
Hong Kong [8] and Beijing [9] have demonstrated that LNG-
IUS may be an effective and acceptable treatment for idiopath-
ic HMB in perimenopausal Chinese women. In addition, recent 
data indicate higher effectiveness of the LNG-IUS vs. combined 
oral contraceptives (COCs) [10] and oral medroxy-progester-
one acetate [11]. Data in Caucasian women also suggest high 
acceptance and tolerability in everyday clinical practice [12], 
although less favorable reports depending on practice settings 
have also been reported [13]. However, there is limited data 
available from Korea on the treatment practices for women af-
fected by HMB.
Although COCs and oral progestogens, named conventional 
medical treatments (CMTs) in this study, are frequently used as 
first-line therapies for HMB, data is limited on their long-term 
acceptability and tolerability. Available data from the Caucasian 
population suggest poor long-term compliance with CMTs [14,15].
While sufficient data is available from the Caucasian stud-
ies on the everyday clinical use of treatment patterns with the 
LNG-IUS [16,17] or CMTs, there is limited insights available 
from Asian countries such as South Korea. The previously re-
ported MiCo (Mirena or Conventional Medical Treatment for 
Menorrhagia) study [18] was initiated to address these knowl-
edge gaps, and to verify whether the LNG-IUS improves clinical 
outcomes compared to CMTs in Asian patients, similar to the 
data shown in European and North American clinical studies. 
This publication now reports a sub-analysis of this large Asia-
Pacific non-interventional study, with focus on the patient 
group from South Korea. The proportion of Korean patients 
was one third of the entire study population, representing the 
largest group in the study. In view of the limited data available 
on this subject, the outcome of this subgroup analysis can be 
discussed in relation to the overall result and studies conducted 
in other regions to confirm comparable results. Furthermore, it 
will reflect the unique clinical features of population. Consider-
ing that LNG-IUS is currently well established in medical treat-
ment practice in Korea, this study allows a better understand-
ing of its application.
Materials and methods 
This global non-interventional study is a prospected, cohort 
study which enrolled women aged 18 to 45 years with com-
plaints of idiopathic HMB over several cycles with no intention 
to conceive within one year from the start of therapy. A total 
of eight countries participated from Asia, including China, 
Taiwan, Hong Kong, Indonesia, Malaysia, Pakistan, South 
Korea, and Thailand. The Korean arm of the study recruited 
209 patients from 19 sites (32.3% of the total study popula-
tion) within South Korea during September 2008 to December 
2010. The study protocol was approved by the local inde-
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Women between the ages of 18 to 45 (inclusive) not intending to
become pregnant during the next year
Contraindications and warnings with the study drugs as per the
summary of product characteristics
Women complaining of heavy menstrual bleeding over several
consecutive cycle
Women on hormone replacement therapy
Women without structural or histological abnormality of the uterus Women with symptoms such as intermenstrual or post-coital 
bleeding, unless pathology is excluded with an endometrial biopsy 
Women eligible for pharmacological treatment of fibroids (size <3 cm
in diameter without distortion of the uterine cavity)
Abdominally palpable fibroids
Intra-cavitary fibroids
Uterine length >12 cm on ultrasound or hysteroscopy
Women on anticoagulants or other treatments (e.g., copper IUD) 
known to cause menorrhagia
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pendent ethics committee or institutional review board when 
required. All participants provided written, informed consent 
before study enrolment. The study was conducted in accor-
dance with the amended version of the Declaration of Helsinki 
and in compliance with the principles of Good Clinical Practice. 
The study was registered at ClinicalTrials.gov (NCT00864136, 
March 9, 2010). The inclusion and exclusion criteria are de-
scribed in Table 1. Participating physicians were asked to com-
plete a questionnaire to understand their preferred lines of 
therapy and average time spent on counseling a patient about 
HMB. Physicians participating in the study treated patients with 
LNG‐IUS and CMTs in routine practice. The study enrolment 
did not warrant additional investigations and the choice of 
treatment was determined by the treating physician, who pre-
scribed LNG-IUS or CMTs according to their clinical judgment, 
independent of enrolment into the study. The physicians had 
to document at least one and maximum three follow-up visits 
during a one-year timeframe and standardized case report 
forms were used for documentation, which formed the basis 
for all analysis. At baseline, demographic data, gynecologic 
and obstetrical history, and data on the duration of idiopathic 
HMB and previous treatments, if any, were documented. In 
addition, subjective evaluation of the amount of bleeding 
(5-degree Likert like scale, none to very heavy), the number of 
bleeding/spotting days during the last 30 days as informed by 
the questions, and subjective evaluation of menstrual pain and 
premenstrual symptoms (PMS) (4-degree Likert like scale, none 
to severe) were collected. Documentation of each item was 
mandatory at each follow-up visit, along with documentation 
of concomitant medications, change of therapy and adverse 
events. At the last visit (at 12 months or at premature discon-
tinuation), the subjective satisfaction (by patient) as well as 
final assessment of the efficacy and the tolerability of the treat-
ment (by physician) was collected. 
The primary outcome measure of this study was the cumula-
tive continuation rate at 12 months stratified by the history of 
previous treatment(s) for HMB. Observations up to 402 days 
(365 days+6 weeks) were considered to represent this continu-
ation rate. In addition, secondary outcome parameters such 
as bleeding pattern, patient satisfaction at end of documenta-
tion, impact of the therapy in terms of patient-derived health 
outcomes (based on the Menorrhagia Multi-Attribute Scale [19] 
and to be reported elsewhere) and safety profile were included 
as part of the study. These variables were analyzed at one year 
after start of the therapy or at the end of therapy (if earlier). 
The analyses were primarily of an explorative and descriptive 
nature, performed using summary statistics for categorical and 
quantitative (continuous) data. Fisher’s exact test was used for 
the calculation of cumulative continuation rate, and analyzed 
with Kaplan-Maier plot. Adverse events were summarized us-
ing the MedDRA (Medical Dictionary for Regulatory Activities) 
coding system version 14.0 by system organ classes and pre-
ferred terms.
Results
A total of 18 physicians from South Korea completed the phy-
sician questionnaire. Most physicians spent 6 to 10 minutes 
per patient discussing HMB, which was in line with overall data 
from the Asia-Pacific region (data discussed elsewhere). The 
most common first-line treatments for idiopathic HMB were 
COCs and NSAIDs, and LNG-IUS and COCs were the most pre-
ferred second-line option, while GnRH analogs and oral pro-
gestogens were the preferred third-line options (Fig. 1). Out of 
a total of 647 women from the 8 participating Asian countries, 
a total of 209 patients (32.3%) (LNG-IUS, 169; CMTs, 40) were 
recruited from South Korea. All patients were included for the 
safety analysis (full analysis set), while the per-protocol sample 
of 187 patients (LNG-IUS, 154; CMTs, 33) were included for ef-
ficacy analysis. 
Fig. 1. Current treatment preferences in the management of HMB 
(multiple responses allowed). Physicians (n=18) were asked to select 
1st, 2nd, and 3rd line treatments for HMB according to their current 
prescription preference. Multiple choices were allowed for each catego-
ry. The graph shows the treatment options by percentage of physicians 
choosing them. HMB, heavy menstrual bleeding; COCs, combined oral 
contraceptives; NSAIDs, non-steroidal anti-inflammatory drugs; LNG-
IUS, levonorgestrel-releasing intrauterine system; GnRH, gonadotropin-
releasing hormone.
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Demographic and baseline bleeding characteristics of the 
study population are presented in Table 2. The majority of the 
patients (approximately two-thirds) belonged to the age group 
of 36 to 45 years. The baseline characteristics of patients in 
both the treatment arms were comparable. Out of the 209 
participants, 121 women (57.9%) had a history of gynecologi-
Table 2. Demographic and baseline bleeding characteristics of the study population
LNG-IUS (n=169) CMTs (n=40)
Age (yr)
18–25 0 (0) 10 (25)
26–35 43 (25.4) 15 (37.5)
36–45 116 (68.6) 14 (35)
Missing 10 (5.9) 1 (2.5)
Body mass index (kg/m2)
<18.5 7 (4.1) 3 (7.5)
18.5 to <25 125 (74) 28 (70)
25 to <30 22 (13) 7 (17.5)
≥30 5 (3) 1 (2.5)
Missing 10 (5.9) 1 (2.5)
Education
No schooling 1 (0.6) 1 (2.5)
Primary 2 (1.2) 1 (2.5)
Secondary 39 (23.1) 12 (30)
Tertiary (i.e., university, academy) 107 (63.3) 26 (65)
Missing 20 (11.8) 0 (0)
No. of live births
Nullipara 11 (6.5) 17 (42.5)
Para 1–2 149 (88.1) 20 (50)
Para 3 7 (4.1) 1 (2.5)
Missing 2 (1.2) 2 (5.0)
Premenstrual symptoms
No 40 (23.7) 13 (32.5)
Mild 78 (46.2) 17 (42.5)
Moderate 34 (20.1) 6 (15)
Severe 10 (5.9) 3 (7.5)
Missing 7 (4.1) 1 (2.5)
No. of bleeding days in last 30 days 4.7±2.3 5.3±3.1
No. of spotting days in last 30 days 3.5±3.6 2.7±3.1
No. of previous treatments for HMB
None 149 (88.2) 26 (65)
At least 1 treatment 16 (9.4) 13 (32.5)
Missing 4 (2.4) 1 (2.5)
Values are presented as n (%) or mean±SD.
LNG-IUS, levonorgestrel-releasing intrauterine system; CMT, conventional medical treatment; P, para; HMB, heavy menstrual bleeding.
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cal disorder or procedure, most commonly Caesarian section, 
uterine fibroids, and cervical dilatation and curettage. Majority 
of the patients (LNG-IUS, 88.2%; CMTs, 65.0%) did not have 
a previous menorrhagia treatment. The most frequent previous 
therapies were surgery and COCs. 
The efficacy population (per-protocol pample cohort, n=187) 
was evaluated for cumulative treatment continuation rate 
within a timeframe of 402 days (1 year+6 weeks). The cumu-
lative treatment continuation rate in the LNG-IUS arm was 
significantly higher than in the CMT arm (85.1% vs. 48.5%, 
respectively; P<0.0001). In the LNG-IUS group, previous treat-
ment experience had no significant impact on the continuation 
rate (continuation rate with vs. without previous treatment 
experience: 87.5% vs. 84.4%, respectively). In the CMT group, 
however, the treatment continuation rate was lower with pre-
vious treatment experience (40.0%), as compared to treatment 
naïve patients (52.2%). The odds ratio for discontinuation in 
the CMT vs. the LNG-IUS groups was 6.05 (95% confidence 
interval, 2.68 to 13.66). The duration until discontinuation 
was compared via a Kaplan-Meier analysis. In this evaluation, 
for patients without documented end of therapy, the duration 
of observation was computed and interpreted as censored 
duration until discontinuation. The Kaplan-Meier plot of the 
two treatment groups is shown in Fig. 2. Fig. 2 shows that 
the proportion of patients without discontinuation of therapy 
decreased very slowly in the LNG-IUS group, compared to the 
CMT group. While the proportions for the CMT group de-
creased below 50% within the observation period, more than 
80% of the LNH-IUS group still continued their treatment. 
Stratification of continuation rate by age, body mass index or 
duration of HMB symptoms did not have a marked impact on 
these overall results (data not shown). 
Among the 18.8% patients who discontinued treatment 
in the LNG-IUS group, most common reason for discontinua-
tion was bleeding, while among the 51.5% of patients who 
discontinued the treatment in the CMT group, the most com-
mon reason for discontinuation was switch to other treatment 
except other personal reason (Table 3).
The number of bleeding and spotting days during the ob-
servation period is shown in Fig. 3. Overall, a larger decrease 
of bleeding days was observed from the initial visit to the last 
follow up within the LNG-IUS group (mean±SD, 1.6±3.4 days) 
as compared to the CMT group (mean±SD, 3.2±1.5 days) (Fig. 
3A). The mean reduction in spotting days of LNG-IUS and CMT 
group was 1.8 day and 0.6 days, respectively, and there was an 
increase of 2.3 days in the mean number of spotting days in the 
LNG-IUS group compared to baseline spotting days (mean±SD, 
3.5±3.6) (Fig. 3B). The subjective evaluation of the amount of 
bleeding showed a higher percentage of patients reporting 
“no” or “slight” bleeding in the LNG-IUS group, compared to 
the CMT group where the patients reported higher proportion 
of “slight” or “moderate” bleeding (Fig. 4)—this difference 
was observed already starting from the first follow up and 
increased over time. In addition, the LNG-IUS also offered bet-
ter control of other associated symptoms, with higher propor-
tion of women on LNG-IUS experiencing complete remission 
of menstrual pain (last documented visit; LNG-IUS, 104/154, 
67.5%; CMTs, 15/30, 50.0%). Also, the proportion of patients 
on LNG-IUS who reported complete resolution of PMS, were 
Fig. 2. Kaplan-Maier plot of time to discontinuation of treatment strati-
fied by treatment group: levonorgestrel-releasing intrauterine system vs. 
conventional medical treatment.
Table 3. Reasons for discontinuation
LNG-IUS (n=154) CMTs (n=33)
Switch to other treatment 6 (3.9) 5 (15.2)
Wish for pregnancy 2 (1.3) 0 (0)
Adverse event 5 (3.2) 0 (0)
Bleeding 9 (5.8) 0 (0)
Other medical reason 5 (3.2) 1 (3)
Other personal reason 2 (1.3) 11 (33.3)
Total 29 (18.8) 17 (51.5)
Values are presented as n (%).
LNG-IUS, levonorgestrel-releasing intrauterine system; CMT, conven-
tional medical treatment.
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comparable to the CMTs group (last documented visit; LNG-
IUS, 103/154, 66.9%; CMTs, 23/30, 76.7%). The physicians’ 
evaluation (Table 4) indicated better efficacy and tolerability 
with LNG-IUS as compared to CMTs in the management of 
HMB, which was concordant with the patient-reported out-
comes. In this study, the following points showed differences in 
clinical practice when comparing the Korean patients with the 
overall results. In the question about previous HMB treatment, 
the number of “no treatment received” in the entire group 
was 355 (54.9%) compared to 175 (83.7%) in the South 
Korean group. This would mean that physician’s active inter-
vention, at least from these figures, for the treatment of HMB 
is less in Korea than in the overall population of this study. 
Regarding the type of treatment chosen in the conventional 
therapy group, use of antifibrinolytics only or combined hor-
mone and antifibrinolytic treatment group in total study group 
was 39 (23.8%) and 36 (22%), respectively. In comparison, in 
the South Korean group, antifibrinolytics were not chosen, and 
hormonal therapy was favored in 97.5% of cases (Table 5).
The nature and frequency of adverse events and treatment-
related adverse events occurring during therapy were con-
sistent with the established safety profile of the treatments 
administered. Overall, adverse events were reported in 17.1% 
(29/169) patients in the LNG-IUS group and 12.5% (5/40) in 
the CMTs group, of which 14.2% (24/169) in the LNG-IUS 
group and 10% (4/40) in the CMT group were treatment-re-
lated. In the LNG-IUS group, the most common adverse events 
were reproductive system and breast disorders (n=17, 10.1%), 
including HMB (n=7) and uterine hemorrhage (n=7). No seri-
ous adverse events leading to prolonged bleeding or requiring 
hospitalization were reported in the LNG-IUS or CMTs group.
 
Fig. 3. Number of bleeding days (A) and spotting days (B) during last 30 days according to treatment group. LNG-IUS, levonorgestrel-releasing in-
trauterine system; CMT, conventional medical treatment.
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Discussion
Even though various treatment modalities have been intro-
duced for the management of HMB in South Korea, there 
is limited data on the real-life clinical practice and treatment 
choices. This study reports real-world treatment preferences of 
HMB treatments in South Korea, providing insights to the cur-
rent practices and clinical decision making processes, which to 
the best knowledge of the authors is a first of its kind. 
This prospective non-interventional cohort study compares 
LNG-IUS and CMTs, which are the two most commonly used 
medical treatment modalities for idiopathic HMB. The term 
‘CMTs’ encompasses hormonal treatments such as COCs and 
oral or injectable progestogens. Previous history of HMB treat-
ments is also taken into account, as the continuation rate was 
also analyzed stratified by exposure to previous treatments. 
The observational setting used in this study provides us a real-
life model, with routine clinical criteria used in the diagnosis of 
HMB, and treatment allocation made on the discretion of the 
investigator as in normal clinical practice. This is probably one 
of the major strengths of this study. In contrast, the routine 
interventional clinical studies of HMB, with rigorous methodol-
ogy for menstrual blood loss measurement (quantify blood loss 
measurement method: alkaline hematin method, the pictorial 
blood assessment chart method) and strict inclusion/exclusion 
criteria, have high screening failure rates, and may miss out 
the routine clinical spectrum of HMB patients [11]. Therefore, 
these latter studies represent results from a highly selected pa-
tient population, which may not be applicable to HMB patients 
seen in everyday clinical practice.
This study is an observational cohort study, which can be 
considered as one of the major limitations of this study. Due to 
the observational nature, both cohorts in the treatment arms 
are not necessarily identical. However, in this study the baseline 
characteristics of both the cohorts were comparable. The di-
agnosis of HMB was made based on patients´ subjective com-
plaints, as per the existing international guidelines on HMB [1]. 
This study does not employ objective measurements such as 
alkaline hematin method for quantification of menstrual blood 
loss, due to the observational nature of study methodology. 
However, such methods only have theoretical importance, as 
they are not practical to apply in routine clinical use, and hence 
should not form the basis of clinical diagnosis. 
One of the glaring findings from this study, both from the 
Korean as well as the overall Asian population, is that the clini-
cians allocate only a limited time slot in counseling patients on 
HMB. This is one of the aspects of HMB care that needs special 
attention in our region. The study results also indicate that de-
spite availability of global data on efficacy of LNG-IUS in HMB, 
CMTs are still considered as first-line therapies for HMB in Ko-
rea, while the LNG-IUS is considered mostly as a 2nd line treat-
ment option. Higher patient load and shorter time allocated per 
patient in Korea may be one the reasons behind this preference 
of CMTs over LNG-IUS, as there may be a perception among 
the clinicians that CMTs may take shorter time to initiate vs. 
LNG-IUS, which requires pre-insertion counseling and fitting. 
In this study, even though antifibrinolytics are proven as con-
ventional treatment for HMB treatment through the literature 
and guidelines, in almost all Korean cases physicians chose the 
use of hormonal treatment for HMB for their patients, in this 
study. The present study results demonstrated a clear superior-
ity of the LNG-IUS compared to the CMTs in the treatment of 
HMB for the outcomes measured, including continuation rate, 
treatment efficacy, and reduction in the number of bleeding 
Table 4. Efficacy of the treatments at the last follow-up as assessed 
by the physician
LNG-IUS CMTs
Very good 53 (34.4) 2 (6.1)
Good 64 (41.6) 11 (33.3)
Sufficient 20 (13) 14 (42.4)
Insufficient 14 (9.1) 5 (15.2)
Missing 3 (1.9) 1 (3)
Total 154 (100) 33 (100)
Values are presented as n (%).
LNG-IUS, levonorgestrel-releasing intrauterine system; CMT, conven-
tional medical treatment.
Table 5. The physician’s treatment choice for HMB in the conventional 
therapy group
HMB treatment chosen Asia total Korea
Missing 5 (3.0) 1 (2.5)
Hormonal treatment 84 (51.2) 39 (97.5)
Antifibrinolytic treatment 39 (23.8) 0 (0)
Hormonal and antifibrinolytic
treatment 36 (22) 0 (0)
Total 164 (100.0) 40 (100.0)
Values are presented as n (%).
HMB, heavy menstrual bleeding.
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days, dysmenorrhea and PMS related symptoms. The difference 
between the treatments in the continuation rate at 12 months 
was more than 30%, which can be considered as robust evi-
dence of clear clinical benefit of the LNG-IUS over CMTs in the 
treatment of HMB. The continuation rate was higher with the 
LNG-IUS, regardless of the CMT treatment type. 
The present study results are in line with previous random-
ized clinical studies, comparing the LNG-IUS to oral progestins 
and combined oral contraceptives [7]. Thus the results can be 
considered to confirmatory of the previous studies using more 
rigorous methodologies.
The continuation rates in the LNG-IUS group were similar 
regardless of exposure to previous HMB treatment, whereas 
in the CMT group, continuation rate was clearly lower among 
patients who had already tried at least one treatment for HMB. 
This is an interesting novel finding, as continuation rates or 
other clinical outcomes have usually not been reported sepa-
rately for naïve and non- naïve patients in most HMB trials. 
Treatment discontinuations in the CMT group were mostly 
related to switch to other treatment or personal reasons. The 
former can be considered as a sign of insufficient treatment ef-
ficacy, while it was not possible to collect detailed information 
on the personal reasons indicated as reason for discontinua-
tion. The occurrence of adverse events was low, and serious 
adverse events occurred at a frequency of <1%. While the ad-
verse event rate in the LNG-IUS group was higher than in the 
CMT group, a comparison of the crude incidences of adverse 
events between the treatment groups is hindered by the dispa-
rate observation and exposure time in the two groups, with a 
longer, continuous exposure and observation time in the LNG-
IUS group compared to conventional treatment for the women 
included in the safety analysis. 
This study provides us with insights into the management 
of HMB in Asia in real-life situations. It concurs with the data 
which has been the basis of international HMB treatment 
guidelines, placing the LNG-IUS as the first-line treatment for 
HMB [1,20]. The data from this study could also help in under-
standing the typical characteristics of Asian HMB patient popu-
lation, showing that they benefit equally from the treatment 
with the LNG-IUS, as compared to previously published studies 
in Caucasians [7]. In view of these conclusive data, LNG-IUS 
should be considered as the first-line treatment for the man-
agement of HMB in Korean women, in line with existing inter-
national guidelines.
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